林金棠;谢甦;李丽红;黄建军;包刚;李珀;
LIN Jintang;XIE Su;LI Lihong;HUANG Jianjun;BAO Gang;LI Bo;Guizhou Medical University;Affiliated Hospital of Guizhou Medical University;

• 1:贵州医科大学
• 2:贵州医科大学附院

摘要(Abstract)：

目的:观察薯蓣丸协助乳腺癌术前表柔比星联合环磷酰胺(EC)化疗疗效。方法:60例乳腺癌术前行EC化疗4个周期,将患者随机均分为中药组和对照组,中药组在第3个周期化疗结束的第1天开始服用薯蓣丸方颗粒剂至第4周期化疗结束(共30 d),对照组仅常规化疗,观察2组患者手术前化疗前后卡氏评分(KPS)、细胞增殖核抗原(Ki-67)、孕激素受体(PR)、雌激素受体(ER)的阳性病例数变化。结果:化疗后中药组KPS评分提高的病例数高于对照组,稳定及无效低于对照组(P<0.05);化疗前,中药组和对照组Ki-67、PR、ER阳性病例数相当(P>0.05);化疗后中药组Ki-67阳性病例数低于对照组化疗后(P<0.05),而中药组和对照组PR、ER阳性病例数在治疗前后差异无统计学意义(P>0.05)。结论:薯蓣丸可提高乳腺癌患者术前化疗生存质量,降低Ki-67的阳性表达率,但不影响ER、PR的阳性表达率。
Objective: To observe the adjunctive therapy efficacy of Shuyu pill in treatment of breast cancer patients with chemotherapy of EC before operation. Methods: The 60 patients were randomly divided into two groups: TCM group( 30 cases) and control group( 30 cases). TCM group were given Shuyu pill from the first day after the third period of EC chemotherapy to last day of the final period of EC chemotherapy,which lasted 30 days,while control group were just given normal EC chemotherapy. The indexes of KPS,ER,PR and Ki-67 positive expression were observed and compared between two groups. Results: The KPS scores of TCM group was significantly higher than those of control group( P < 0. 05). Before EC chemotherapy,ER,PR and Ki-67 positive expression cases were not statistically different between TCM group and control group( P > 0. 05). However,after EC chemotherapy,the number of Ki-67 positive expression cases in TCM group was significantly lower than that of control group( P < 0. 05) while the differences in the numbers of PR and ER positive expression cases between TCM group and control group showed no statistical significance( P > 0. 05). Conclusion: The Shuyu pill can improve life quality of patients. It can decrease Ki-67 positive expression rate but cannot affect the rate of positive expression of ER,PR.

关键词(KeyWords)： 乳腺肿瘤;抗肿瘤联合化疗方案;薯蓣丸;细胞增殖核抗原;雌激素受体;孕激素受体
breast cancer;anti-tumor chemotherapy regimen;Shuyu pill;cell proliferation nuclear antigen;estrogen receptor;progesterone receptor

Abstract:

Keywords:

基金项目(Foundation): 贵州省卫生计生委科学技术基金项目(WT2014-11)

作者(Authors): 林金棠;谢甦;李丽红;黄建军;包刚;李珀;
LIN Jintang;XIE Su;LI Lihong;HUANG Jianjun;BAO Gang;LI Bo;Guizhou Medical University;Affiliated Hospital of Guizhou Medical University;

DOI: 10.19367/j.cnki.1000-2707.2015.11.021

参考文献(References)：

• [1]朱建华,周洪园.乳腺恶性肿瘤298例临床病理分析[J].西部医学,2006(1):316-317.
• [2]陈彦.加味四君子汤对乳腺癌化疗毒副作用的影响[J].中医药导报,2009(1):38.
• [3]梁存河,王宇.乳腺外科查房释疑[M].北京:人民军医出版社,2011:171.
• [4]苏立夫.ER、PR、Ki-67、HER-2在乳腺癌新辅助化疗中表达变化及其对疗效预测的研究[D].大连医科大学,2013.
• [5]李少林,任国胜,陈晓晶,等.乳腺癌的基础理论和临床实践[M].北京:科学出版社,2008:432.
• [6]高振华.中医药防治肿瘤化疗毒副反应临床研究进展[J].中国中医药信息杂志,2013(11):104-105.
• [7]郑筱祥,杨勇,叶剑锋,等.东阿阿胶的升白作用及机制研究[J].中国现代药学杂志,2005(2):102-105.
• [8]郭亚飞,迟涛,袁中旭,等.E-cad和Ki-67的表达与乳腺癌腋窝淋巴结转移的关系[J].临床心身疾病杂志,2014(20):6-7.
• [9]傅晓艳.乳腺癌Ki-6抗原表达与腋淋巴结转移和组织学分级的关系[J].蚌埠医学院学报,2005(1):17-19.
• [10]陈红秋,粟连秀,杨达平,等.ER、PR、Cerb B-2及P53在乳腺癌中的表达及意义[J].广西医学,2008(3):343-344.
• [11]刘英,黄建军.乳腺癌新辅助化疗前后ER、PR、HER-2、EGFR、CK5/6的表达及预测化疗效果的意义[J].贵阳医学院学报,2014(5):682-687.

文章评论(Comment)：